Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAR levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

被引：20
作者：
Verdú, J
Marco, P
Benlloch, S
Sanchez, J
Lucas, J
机构：
[1] Gen Hosp Alicante, Dept Haematol, Secc Hemostasia & Trombosis, Alicante 03010, Spain
[2] Gen Hosp Alicante, Unidad Invest, Alicante 03010, Spain
来源：
THROMBOSIS AND HAEMOSTASIS | 2006年 / 95卷 / 03期
关键词：
D O I：
10.1160/TH-05-09-0620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：585 / 586
页数：2
相关论文
共 10 条
  • [1] A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
    Brouwers, GJ
    Vos, HL
    Leebeek, FWG
    Bulk, S
    Schneider, M
    Boffa, M
    Koschinsky, M
    van Tilburg, NH
    Nesheim, ME
    Bertina, RM
    García, EBG
    [J]. BLOOD, 2001, 98 (06) : 1992 - 1993
  • [2] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Eichinger, S
    Schönauer, V
    Weltermann, A
    Minar, E
    Bialonczyk, C
    Hirschl, M
    Schneider, B
    Quehenberger, P
    Kyrle, PA
    [J]. BLOOD, 2004, 103 (10) : 3773 - 3776
  • [3] Quantification of thrombin activatable fibrinolysis inhibitor (TAR) gene polymorphism effects on plasma levels of TAR measured with assays insensitive to isoform-dependent artefact
    Frère, C
    Morange, PE
    Saut, N
    Tregouet, DA
    Grosley, M
    Beltran, J
    Juhan-Vague, I
    Alessi, MC
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (02) : 373 - 379
  • [4] Development of a genotype 325-specific proCPU/TAFI ELISA
    Gils, A
    Alessi, MC
    Brouwers, E
    Peeters, M
    Marx, P
    Leurs, J
    Bouma, B
    Hendriks, D
    Juhan-Vague, I
    Declerck, PJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (06) : 1122 - 1127
  • [5] Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
    Guimaraes, AHC
    van Tilburg, NH
    Vos, HL
    Bertina, RM
    Rijken, DC
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) : 659 - 665
  • [6] Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene:: evidence that plasma TAFI antigen levels are strongly genetically controlled
    Henry, M
    Aubert, H
    Morange, PE
    Nanni, I
    Alessi, MC
    Tiret, L
    Juhan-Vague, I
    [J]. BLOOD, 2001, 97 (07) : 2053 - 2058
  • [7] Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe
    Juhan-Vague, I
    Morange, PE
    Aubert, H
    Henry, M
    Aillaud, MF
    Alessi, MC
    Samnegård, A
    Hawe, E
    Yudkin, J
    Margaglione, M
    Di Minno, G
    Hamsten, A
    Humphries, SE
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (05) : 867 - 873
  • [8] High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
    Leebeek, FWG
    Van Goor, MPJ
    Guimaraes, AHC
    Brouwers, GJ
    De Maat, MPM
    Dippel, DWJ
    Rijken, DC
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (10) : 2211 - 2218
  • [9] Trégouet DA, 2001, HUM GENET, V109, P191
  • [10] Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
    van Tilburg, NH
    Rosendaal, FR
    Bertina, RM
    [J]. BLOOD, 2000, 95 (09) : 2855 - 2859
1